MIM
ATRA icon

Monashee Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

Monashee Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-400
Closed -$93K – 30
2022
Q1 		$93K Buy
+400
New +$127K 0.03% 36

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Monashee Investment Management's ATRA Position: Q2 2022 in Review

Monashee Investment Management sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 400 shares — an estimated $93K sold.

Monashee Investment Management first reported a position in ATRA in Q1 2022 and held it in 1 quarter. The position peaked at $93K in Q1 2022. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

  • Monashee Investment Management reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Monashee Investment Management sold 400 Atara Biotherapeutics shares in Q2 2022, an estimated $93K.
  • Monashee Investment Management first reported a position in Atara Biotherapeutics in Q1 2022 and held it in 1 quarter.
  • Monashee Investment Management's Atara Biotherapeutics position peaked at $93K in Q1 2022.
  • 134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on Monashee Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.